Clinical Trials Logo

Macular Edema clinical trials

View clinical trials related to Macular Edema.

Filter by:

NCT ID: NCT05345808 Completed - Clinical trials for Retinal Vein Occlusion

Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Retinal vein occlusion (RVO) is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema. Different treatment modalities for macular edema include LASER therapy, antivascular endothelial growth factor (VEGF), and triamcinolone. Aim To detect the efficacy of formulated Triamcinolone Acetonide(TA) injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch.

NCT ID: NCT05343156 Completed - Clinical trials for Diabetic Macular Edema

Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema

Start date: September 18, 2017
Phase: Phase 2
Study type: Interventional

Anti-inflammatory or anti-angiogenic drugs play an ever- increasing role in the treatment of diabetic macular edema (DME). The drug delivery systems, such as injections of corticosteroid and or vascular endothelial growth factor (VEGF) antibodies into the vitreous cavity or slow release drug capsules surgically implanted in the eyes run the risk of surgical complications including infections, hemorrhages and cataracts and place a huge demand on eye care resources significantly increase the risk of cardiovascular events and death. A non-invasive drug delivery platform with steroid eye drops, reaching the back of the eye to treat DME and other retinal diseases would circumvent most of these problems. A novel drug delivery platform is required for ocular therapy. Oculis ehf. has developed a drug delivery platform, which is based on cyclodextrin nanoparticles that dissolve in the tear fluid to form water-soluble drug/cyclodextrin complex nanoparticles. Animal and initial clinical testing has shown the potential for this technology to increase the drug concentration in the eye tissues including the retina and therefore treat retinal diseases like DME.

NCT ID: NCT05337332 Recruiting - Clinical trials for Central Serous Chorioretinopathy

Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

Start date: April 14, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.

NCT ID: NCT05333055 Not yet recruiting - Clinical trials for Diabetic Retinopathy

Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

DRAGONS
Start date: April 11, 2022
Phase:
Study type: Observational

The DRAGONS study is a non-interventional, prospective study that will 1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and 2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.

NCT ID: NCT05324774 Recruiting - Clinical trials for Diabetic Macular Edema

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Start date: February 28, 2022
Phase: Phase 3
Study type: Interventional

Phase III clinical study of the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in patients with diabetic macular edema (DME) in a multicenter, randomized, double-blind, parallel active-controlled study.

NCT ID: NCT05324592 Completed - Clinical trials for Diabetic Macular Edema

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Start date: February 26, 2021
Phase: Phase 1
Study type: Interventional

A multicenter, randomized, double-blind, parallel-controlled phase I trial comparing the safety, pharmacokinetics and efficacy of 9MW0813 and aflibercept (EYLEA®) after a single dose in patients with diabetic macular edema (DME).

NCT ID: NCT05301751 Active, not recruiting - Clinical trials for Diabetic Macular Edema

AG-73305 Single Ascending Dose Cohort Study in DME

Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate 4 dosing cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME).

NCT ID: NCT05290948 Active, not recruiting - Macular Edema Clinical Trials

Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions

Start date: March 12, 2022
Phase: Phase 2
Study type: Interventional

In this study, which will be performed as a randomized clinical trial, all patients with macular edema with central involvement (central macular thickness greater than 300 μm) and corrected vision less than or equal to 20/40 and better than 20/400 were included in the study. After a thorough eye examination, people are randomly divided into two groups. The first group was treated with intravitreal injection of Bevacizumab in three injections one month apart with receiving oral Acetazolamide tablets of 250 mg twice a day, and the second group was treated with intravitreal injection of Bevacizumab for three Loads are spaced one month apart. Ophthalmologic examinations and corrected visual acuity, as well as macular thickness examination, are repeated with Spectral-domain Optical coherence tomography (SD-OCT) at the beginning of treatment and at the end of the first, second, and third months. At the end of the study, the rate of changes in visual acuity and macular thickness in the eyes in the two groups will be compared and will be statistically analyzed.

NCT ID: NCT05288192 Recruiting - Cataract Clinical Trials

Changes After Suprachoroidal Injection.

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

Changes after suprachoroidal injection are analyzed for statistical analysis.

NCT ID: NCT05282420 Recruiting - Clinical trials for Non-Ischemic Central Retinal Vein Occlusion With Macular Edema

Ranibizumab Versus Aflibercept for CRVO in Young Patients.

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old